Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. by Milojkovic, Dragana et al.
Real-world tyrosine kinase inhibitor treatment pathways,
monitoring patterns and responses in patients with chronic
myeloid leukaemia in the United Kingdom: the UK TARGET
CML study
Dragana Milojkovic,1
Nicholas C. P. Cross,2 Sahra Ali,3
Jenny Byrne,4 Gavin Campbell,5
Fiona L. Dignan,6 Mark Drummond,7





Farooq Wandroo,15 Fenella Willis,16
Fiona Glen,17 Louise Fildes,18
Sarah J. Collington,18 Jacqueline Ryan,18
Richard E. Clark19 and Adam J.
Mead20,21
1Hammersmith Hospital,Imperial College
Healthcare NHS Trust, London,
2University of Southampton, Southampton,
3Castle Hill Hospital, Hull and East
Yorkshire Hospitals NHS Trust,
Cottingham, 4Nottingham City Hospital,
Nottingham University Hospitals NHS
Trust, Nottingham, 5Colchester Hospital
University NHS Foundation Trust,
Colchester, 6Manchester Royal Infirmary,
Manchester University Hospitals
Foundation Trust, Manchester, 7Beatson
Cancer Centre, Glasgow, 8Addenbrookes,
Cambridge University Hospitals NHS
Foundation Trust, Cambridge, 9Sunderland
Royal Hospital, City Hospitals Sunderland
NHS Foundation Trust, Sunderland,
10Belfast City Hospital, Belfast Health and
Social Care Trust, Belfast, 11Royal
Berkshire, Royal Berkshire NHS
Foundation Trust, Belfast, 12Queen
Elizabeth Hospital Birmingham, University
Hospitals Birmingham NHS Foundation





Management of chronic myeloid leukaemia (CML) has recently undergone
dramatic changes, prompting the European LeukemiaNet (ELN) to issue
recommendations in 2013; however, it remains unclear whether real-world
CML management is consistent with these goals. We report results of UK
TARGET CML, a retrospective observational study of 257 patients with
chronic-phase CML who had been prescribed a first-line TKI between 2013
and 2017, most of whom received first-line imatinib (n = 203). Although
44% of patients required ≥1 change of TKI, these real-world data revealed
that molecular assessments were frequently missed, 23% of patients with
ELN-defined treatment failure did not switch TKI, and kinase domain
mutation analysis was performed in only 49% of patients who switched
TKI for resistance. Major molecular response (MMR; BCR-ABL1IS ≤01%)
and deep molecular response (DMR; BCR-ABL1IS ≤001%) were observed
in 50% and 29%, respectively, of patients treated with first-line imatinib,
and 63% and 54%, respectively, receiving a second-generation TKI first
line. MMR and DMR were also observed in 77% and 44% of evaluable
patients with ≥13 months follow-up, receiving a second-generation TKI
second line. We found little evidence that cardiovascular risk factors were
considered during TKI management. These findings highlight key areas for
improvement in providing optimal care to patients with CML.
Keywords: tyrosine kinase inhibitor, chronic myeloid leukaemia, real-world
study, molecular response, CML management.
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Introduction
Tyrosine kinase inhibitors (TKIs) have revolutionised out-
comes for patients with chronic myeloid leukaemia in chronic
phase (CML-CP), with survival rates approaching those of the
general population.1–3 Consequently, key considerations for
optimal patient care have evolved considerably. While the pri-
mary aim remains achievement of molecular response that
minimises the risk of disease progression,4 it is increasingly
evident that complications of the treatment need to be consid-
ered. It is therefore essential for physicians to understand the
best use of the available ABL1-targeting TKIs.4 This is the
principal purpose of the 2013 European LeukemiaNet (ELN)
recommendations, which increased focus on molecular
responses at three, six and 12 months, with patients’ responses
categorised as optimal, warning or failure.4 Patients experienc-
ing failure are at particular risk of disease progression, and the
guidelines recommend that such patients switch treatment and
undergo assessment for BCR-ABL1 kinase domain mutations.4
While the ELN 2013 guidelines state that patients must
achieve a major molecular response [MMR; BCR-ABL1 ≤01%
on the International Scale (IS)] by 12 months for their
response to be considered optimal,4 deeper levels of response,
including MR4 (BCR-ABL1IS ≤001%) and MR45 (BCR-ABL1IS
≤00032%), are also recognised as important milestones.5–7
Some patients with a sustained deep molecular response
(DMR, MR4 or better) may be eligible to attempt treatment-
free remission (TFR).8–11 Clinical trials have demonstrated that
patients are more likely to achieve optimal and deeper
responses to first-line therapy at key ELN milestones when
second-generation (2G) TKIs are used rather than imatinib,
but achievement of responses in real-world practice is less well
studied, particularly in the second-line setting.12–14 Achieve-
ment of ELN-defined responses and how ELN guidelines are
implemented in real-world settings are infrequently explored.
An increased risk of cardiovascular (CV) adverse events
(AEs) has been described in patients receiving 2G- or third-
generation-TKIs compared with imatinib, especially in
patients with pre-existing CV risk factors.13–17 Given the
excellent long-term outcomes in CML, comorbidities are now
a major consideration.18,19 However, in routine UK clinical
practice, it is unclear how physicians assess and manage CV
risk factors or how CV risk factors affect TKI management.
UK TARGET CML (CAMN107CGB12) is a retrospective
observational study of baseline assessment of patients with
CML-CP, TKI treatment pathways, response monitoring pat-
terns and response rates in routine UK National Health Ser-




This retrospective noninterventional study was conducted at
21 UK NHS secondary and tertiary care centres. Data were col-
lected from paper and electronic records. Inclusion criteria
included CML-CP diagnosis at the start of first-line TKI, aged
≥18 years and at ≥6 months of follow-up from the date of first
TKI (between January 2013 and April 2017). Patients
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prescribed first TKI in a clinical trial, and patients in acceler-
ated phase (AP) or blast phase (BP) before initiation of first
TKI were excluded.
Objectives were to describe TKI treatment pathways in the
UK, patient characteristics, practices for assessing and
managing CV risk factors before TKI treatment, responses to
first- and second-line TKI therapy at ELN time points,
recorded reasons for stopping/changing TKIs, adherence to
ELN 2013 recommendations and disease progression fre-
quency and management. AE data were not collected.
Data were analysed using descriptive statistics, with a cut-
off date of 6 June 2018, using Microsoft Excel and STATA
(version 13; StataCorp LLC, College Station, TX, USA). A
study size of 200–250 patients in approximately 20 centres
(maximum of 40 patients/centre) was expected to give a rep-
resentative sample of patients in the UK and provide reliable
quantitative and qualitative variables.
For comparison with ELN, where data were available,
responses were categorised as optimal, warning or failure
according to ELN 2013 recommendations.4 If BCR-ABL1
transcript levels were not available on the IS, unconverted
BCR-ABL1/ABL1 percentages were used to reflect real-world
practices at that centre (all centres used ABL1 as a reference
gene). Two of 14 centres (14%) reported on the IS in 2013,
increasing to 17/21 (81%) in 2017.
Results
Patient demographics and baseline characteristics
Between November 2015 and September 2017, 257 patients
(186 from 14 tertiary centres and 71 from seven general hos-
pitals) were enrolled. Median follow-up by the data cut-off
was 329 months (range, 126–586). Baseline characteristics
are shown in Table I. Clinical characteristics (other than
white blood cell counts) and risk scores at diagnosis were
not well documented.
The first-line TKI was imatinib in the majority of patients
(79%). Reasons for first-line TKI choice were recorded for
<50% of patients; the clinician preference of ‘standard first-line
choice’ and ‘good results expected’ were the most frequently
cited reasons Table SI. First-line imatinib and 2G-TKIs were
prescribed to 31/42 (74%) and 11/42 (26%) patients with high
Sokal scores, respectively, and 23/34 (68%) and 11/34 (32%)
with high European Treatment and Outcomes Study (EUTOS)
scores, respectively. Patients receiving a first-line 2G-TKI were
younger [median, 46 years (95% CI, 41–53 years)] than those
receiving first-line imatinib [median, 55 years (95% CI, 52–
59 years); Mann-Whitney U test, P = 00128].
CV risk factors and other documented comorbidities at
baseline
Among all patients, 149 (58%) had ≥1 recorded comorbidity
at baseline (Table I). Seventy-four patients (36%) receiving
imatinib had CV comorbidities at baseline vs. seven (13%)
receiving a 2G-TKI (Table II). Only 74 patients (29%) had
baseline blood pressure documented; 33 (45%) had stage ≥2
hypertension Table SII.20
Exact levels of baseline blood glucose were documented in
58 patients (23%); documentation occurred more often in
patients treated with first-line 2G-TKI [20/54 (37%)] vs.
imatinib [38/203 (19%)]. Baseline low-density lipoprotein
and total cholesterol levels were recorded in 23 (9%) and 40
(16%) patients, respectively. CV risk assessment tool use was
documented for 10 patients (4%), with the validated QRISK2
tool used in three (1%).
Response monitoring practices
Within 12 months of starting first-line TKI, 250 patients
(97%) had ≥1 real-time quantitative polymerase chain reac-
tion (RQ-PCR) assessment and 221 patients (86%) had ≥3
RQ-PCR assessments. Two-hundred and four (79%), 177
(69%), and 162 (63%) patients had assessments at the three-,
six-, or 12-month ELN milestones (regardless of TKI line),
respectively. Cytogenetic testing (chromosome banding anal-
ysis or fluorescence in situ hybridisation) was conducted less
frequently. Frequency of assessments at ELN milestones on
first and second TKI are described in Table III.
First-line TKI therapy
Median follow-up duration on first-line TKI and molecular
responses to first-line TKI therapy are shown in Table IV. Time
to discontinuation of first TKI for patients on imatinib vs. 2G-
TKI is shown in Fig 1. For patients receiving imatinib or nilo-
tinib, respective median starting doses were 400 or 600 mg/day,
while 24/203 (12%) and 8/50 (16%) had dose reductions, and
14% and 12% had dose interruptions, respectively.
Quantifiable molecular or cytogenetic assessments were
performed at ≥1 ELN milestone during first-line TKI in 223
patients (87%) (Fig 2). Forty-eight patients had ≥1 failure,
11 (23%) remained on first-line TKI {median follow-up,
138 months [interquartile range (IQR), 128–25.9]}, and 37
(77%) switched TKIs [median follow-up, 251 months (IQR,
143–32.6)].
Second-line TKI therapy
At least one TKI switch occurred in 113 patients (44%); 54
(21%) switched more than once. Reasons for the first switch
were resistance in 73 (65%), intolerance in 38 (34%) and
other reasons in two (2%) (Table SIII). Thirteen patients
(12%) switched to imatinib, 68 (60%) to nilotinib, 20 (18%)
to dasatinib, 11 (10%) to bosutinib and one (1%) to pona-
tinib (Table SIV). For patients receiving second-line ima-
tinib, nilotinib, dasatinib and bosutinib, median starting
doses (range) were 400 (200–400), 600 (200–800), 100 (50–
100) and 300 (100–500) mg/day, respectively.
Tyrosine kinase inhibitor use in the real world
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Male 144 (56) 119 (59) 25 (46) 24 (48)
Female 113 (44) 84 (41) 29 (54) 26 (52)










Time from CML diagnosis to start of first
TKI, median (IQR), days
70 (10–200) 80 (20–203) 60 (10–110) 60 (10–110)
Assessments prior to first-line TKI, n (%)
RQ-PCR 169 (66) 140 (69) 29 (54) 26 (52)
Qualitative PCR (b2a2, b3a2, other) 140 (54) 107 (53) 33 (61) 30 (60)
CBA 180 (70) 146 (72) 34 (63) 31 (62)
FISH 155 (60) 117 (58) 38 (70) 34 (68)
CBA or FISH (bone marrow) 154 (60) 119 (59) 35 (65) 32 (64)
CBA or FISH (peripheral blood) 54 (21) 45 (22) 9 (17) 9 (18)
Both CBA/FISH and RQ-PCR 139 (54) 117 (58) 22 (41) 20 (40)
Treatment for CML prior to first-line
TKI, n (%)
Yes 126 (49) 97 (48) 29 (54) 26 (52)
Prior treatment*,†
Hydroxycarbamide 116 (92) 89 (92) 27 (93) 24 (92)
Leukapheresis 2 (2) 2 (2) 0 0
Anagrelide 1 (1) 1 (1) 0 0
Interferon 1 (1) 1 (1) 0 0
Aspirin 1 (1) 0 1 (3) 1 (4)
No 128 (50) 104 (51) 24 (44) 23 (46)
Unknown 3 (1) 2 (1) 1 (2) 1 (2)
Ph chromosome at baseline
Yes 212 (82) 175 (86) 37 (69) 35 (70)
No 3 (1) 1 (<1) 2 (4) 2 (4)
Unknown 42 (16) 27 (13) 15 (28) 13 (26)
Clinical characteristics
WBC count, median (IQR), 109/l 824 (312–1773) 770 (312–1580) 929 (323–2014) 921 (325–1989)
Unknown, n (%)‡ 4 (2) 1 (<1) 3 (6) 2 (4)
Platelet count, median (IQR), 109/l 4040 (2525–6030) 3935 (2448–6030) 4390 (3390–5780) 4410 (3428–5893)
Unknown, n (%)‡ 14 (5) 11 (5) 3 (6) 2 (4)
Basophils, median (IQR), % 39 (20–70) 33 (20–60) 50 (23–80) 40 (23–83)
Unknown, n (%)‡ 59 (23) 46 (23) 13 (24) 13 (26)
Eosinophils, median (IQR), % 20 (11–37) 20 (11–35) 20 (13–37) 20 (13–30)
Unknown, n (%)‡ 58 (23) 45 (22) 13 (24) 13 (26)
Blasts, median (IQR) (%) 20 (10–48) 20 (10–34) 30 (16–84) 30 (15–60)
Unknown, n (%)‡ 101 (39) 77 (38) 24 (44) 23 (46)
Spleen size below costal margin,
median (IQR), cm§
13 (00–101) 10 (00–101) 40 (00–103) 20 (00–100)
Unknown, n (%)‡ 85 (33) 67 (33) 18 (33) 17 (34)
Sokal risk score, n (%)¶
Low risk 52 (20) 43 (21) 9 (17) 8 (16)
Intermediate risk 54 (21) 41 (20) 13 (24) 13 (26)
High risk 42 (16) 31 (15) 11 (20) 9 (18)
No score recorded and required components
not all recorded
109 (42) 88 (43) 21 (39) 20 (40)
EUTOS score, n (%)**
Low risk 110 (43) 90 (44) 20 (37) 19 (38)
High risk 34 (13) 23 (11) 11 (20) 9 (18)
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Median follow-up duration after switching to second TKI
was 237 months (range, 12–541) (Table V). MMR at any
time and DMR at any time were observed in 37/51 (73%)
and 21/51 (41%) patients, respectively, with ≥13 months’ fol-
low-up on second line. Molecular responses to second-line
TKI for all patients regardless of follow-up duration are
shown in Table V.
Of the 113 patients who switched TKI at least once, 18
(16%) had failure on second-line TKI (Figure S1), seven
(39%) remained on that TKI (median follow-up,
243 months (IQR, 116–31.0)], while 11 (61%) switched
again [median follow-up, 275 months (IQR, 164–33.8)].
Kinase domain mutation analysis
BCR-ABL1 kinase domain mutational analysis was performed
prior to the first switch in 24 patients (21%), including 20
(27%) who switched due to resistance and four (10%) who
switched due to intolerance or other reasons. Clinically
actionable mutations were identified in six patients
(Table SVI).
Overall TKI pathways
Among all patients, 144 (56%) received only a first-line TKI,
and 59 (23%), 35 (14%), 16 (6%) and three (1%) received
two, three, four and five TKIs, respectively; sequences of TKI
received are described in Table SIV. Eleven patients received
the same TKI in multiple lines of therapy.
Disease progression
Ten patients progressed to AP and/or BP, and 15 patients
died (10 in CP and five after progression). Survival outcomes














No score recorded and required components
not all recorded††
113 (44) 90 (44) 23 (43) 22 (44)
Hasford score, n (%)‡‡
Low risk 25 (10) 19 (9) 6 (11) 5 (10)
Intermediate risk 35 (14) 32 (16) 3 (6) 3 (6)
High risk 19 (7) 13 (6) 6 (11) 4 (8)
No score recorded and required components
not all recorded
178 (69) 139 (68) 39 (72) 38 (76)
Comorbidities, n (%)
None recorded 108 (42) 80 (39) 28 (52) 26 (52)
≥1 recorded§§,¶¶ 149 (58) 123 (61) 26 (48) 24 (48)
CV comorbidities 81 (32) 74 (36) 7 (13) 6 (12)
Diabetes 25 (10) 21 (10) 4 (7) 4 (8)
Respiratory disease 20 (8) 17 (8) 3 (6) 3 (6)
Renal disease 16 (6) 14 (7) 2 (4) 2 (4)
Non-haematological cancer 9 (4) 8 (4) 1 (2) 1 (2)
Hepatic disease 4 (2) 3 (1) 1 (2) 1 (2)
Other 86 (33) 70 (34) 16 (30) 15 (30)
2G-TKI, second-generation tyrosine kinase inhibitor; CBA, chromosome banding analysis; CML, chronic myeloid leukaemia; CV, cardiovascular;
EUTOS, European Treatment and Outcomes Study; FISH, fluorescence in situ hybridisation; IQR, interquartile range; Ph, Philadelphia chromo-
some; RQ-PCR, real-time quantitative polymerase chain reaction; WBC, white blood cell.
*Patients may have received multiple prior treatments.
†Proportion of patients with each prior treatment was calculated out of the total number of patients who received prior treatment.
‡Proportion of patients with unknown clinical characteristics was calculated out of the total number of patients in each column.
§Spleens reported to be ‘normal’ or ‘nonpalpable’ were considered to be 0 cm below the costal margin.
¶Among 148 patients who received any first-line TKI and had an available Sokal risk score at diagnosis, the score was documented for 96 (65%),
and not documented and instead calculated during this analysis for 52 (35%).
**Among 144 patients who received any first-line TKI and had an available EUTOS risk score at diagnosis, the score was documented for 36
(25%), and not documented and instead calculated during this analysis for 108 (75%).
††Includes patients who had a risk category recorded but no score recorded.
‡‡Hasford scores were not collected in case report forms and were calculated if required data were available.
§§Patients may have had multiple comorbidities.
¶¶Proportion of patients with each comorbidity was calculated out of the total number of patients in each column.
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Discussion
The management of CML has undergone dramatic changes;
however, it remains unclear whether real-world practice in
the UK has evolved with these developments. We conducted
the UK TARGET CML study to assess this question, with a
particular focus on (i) TKI treatment pathways, (ii) imple-
mentation of ELN recommendations for molecular-based
patient management, (iii) attainment of DMR with first- and
second-line TKI in real-world practice and (iv) assessment of
baseline CV risk factors.
Despite a relatively short median follow-up (<33 months),
almost half of the patients switched from first-line TKI, most
often due to resistance (65%). In addition, 21% of patients
received ≥3 lines of TKIs. This frequency of TKI switching
was somewhat higher than that observed in prospective clini-
cal trials, such as the pivotal trial of frontline imatinib [Inter-
national Randomized Study of Interferon and STI571










Diabetes 25 (10) 21 (10) 4 (7) 4 (8)
Smoking
Documented* 174 (68) 140 (69) 34 (63) 32 (64)
Current smoker 38 (22) 35 (25) 3 (9) 3 (9)
Ex-smoker 46 (26) 39 (28) 7 (21) 6 (19)
Never smoked 88 (51) 65 (46) 23 (68) 22 (69)
Unclear 2 (1)† 1 (1)† 1 (3)† 1 (3)†
BMI > 30 documented 16 (6) 14 (7) 2 (4) 2 (4)
CV comorbidities
None recorded 176 (68) 129 (64) 47 (87) 44 (88)
≥1 recorded‡,§ 81 (32) 74 (36) 7 (13) 6 (12)
Hypertension 58 (23) 52 (26) 6 (11) 5 (10)
Hyperlipidaemia 28 (11) 26 (13) 2 (4) 2 (4)
Coronary artery disease 14 (5) 12 (6) 2 (4) 2 (4)
Myocardial infarction 11 (4) 10 (5) 1 (2) 1 (2)
Coronary artery bypass graft 9 (4) 8 (4) 1 (2) 1 (2)
Arrhythmias 8 (3) 7 (3) 1 (2) 1 (2)
Cerebrovascular accident 4 (2) 4 (2) 0 0
Transient ischemic attack 4 (2) 3 (1) 1 (2) 1 (2)
Congestive heart failure 3 (1) 2 (1) 1 (2) 1 (2)
Unstable angina 2 (1) 2 (1) 0 0
Percutaneous coronary intervention 2 (1) 2 (1) 0 0
Peripheral vascular disease 2 (1) 2 (1) 0 0
History of CV disease
Not documented 101 (39) 80 (39) 21 (39) 20 (40)
Documentation unknown¶ 1 (<1) 1 (<1) 0 0
Documented** 155 (60) 122 (60) 33 (61) 30 (60)
No history 26 (17) 23 (19) 3 (9) 3 (10)
Details of history not provided 104 (67) 76 (62) 28 (85) 25 (83)
Details of history provided 25 (16) 23 (19) 2 (6) 2 (7)
Family history of CV disease
Not documented 159 (62) 128 (63) 31 (57) 29 (58)
Documentation unknown¶ 1 (<1) 1 (<1) 0 0
Documented 97 (38) 74 (36) 23 (43) 21 (42)
2G-TKI, second-generation tyrosine kinase inhibitor; BMI, body mass index; CV, cardiovascular.
*Proportion of patients in each smoking category was calculated based on the number of patients with documented smoking status.
†Two patients were recorded as ‘does not smoke’; it was unclear whether they were ex-smokers or never smoked.
‡Patients could be listed as having >1 CV comorbidity.
§Proportion of patients with CV comorbidities was calculated based on total number of patients in each column.
¶One patient was transferred from another hospital prior to TKI treatment; it was unclear if this patient’s personal or family history of vascular
disease had been documented prior to TKI treatment.
**Proportion of patients within each category was calculated based on the number of patients who had documented CV disease history.
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(IRIS)], which reported that 34% of patients discontinued
treatment after six years of follow-up, although no other
alternative TKI was available at the time of IRIS recruit-
ment.21 In IRIS long-term follow-up (median, 109 years),
imatinib discontinuation was most frequently attributed to
unsatisfactory therapeutic effect (159%), withdrawal of con-
sent (103%), or AEs (69%).22 Similarly, in the frontline trial
of nilotinib [Evaluating Nilotinib Efficacy and Safety in Clin-
ical Trials–Newly Diagnosed Patients (ENESTnd)], treatment
discontinuations were most frequently due to suboptimal
response/treatment failure or AEs/abnormal laboratory values
(12% each by the five-year data cut-off among patients allo-
cated to nilotinib 300 mg twice daily).14 We found that in
real-world practice, approximately half of patients required a
change of TKI, highlighting the importance of optimal moni-
toring of molecular responses and treatment-related side
effects to ensure proper use of TKIs and timely switching.
These data also demonstrated the ongoing challenge of
establishing a satisfactory, long-term treatment, with multiple
TKI switches being common.
Although 58% of patients had a recorded comorbidity,
patients generally had poorly documented baseline clinical
characteristics and prognostic scores. Demographic and base-
line characteristics were not dissimilar from those of other
real-world cohorts,2,23,24 although prognostic scores were bet-
ter documented (98%) in the Swedish CML registry.2 CV
events have been reported to be increased with 2G-TKIs,13–15
and CV risk factors should therefore be carefully considered
when choosing a TKI. Even with first-line imatinib, it is
important to assess CV risk, given that approximately half of
patients will require a switch to a 2G-TKI at some point.
Although late complications with 2G-TKIs were not fully
understood or evaluable at the time of ELN 2013, the guide-
lines nevertheless recommended continued clinical monitor-
ing of all patients. Several CV risk factors were very poorly
documented in our cohort, and any use of validated CV risk














3 months* 180/223 (81) 143/173 (83) 37/50 (74) 35/47 (74)
6 months† 141/199 (71) 105/154 (68) 36/45 (80) 34/42 (81)
12 months‡ 117/170 (69) 95/132 (72) 22/38 (58) 21/35 (60)
CBA/FISH
3 months* 15/223 (7) 15/173 (9) 0/50 (0) 0/47 (0)
6 months† 9/199 (5) 8/154 (5) 1/45 (2) 1/42 (2)
12 months‡ 2/170 (1) 2/132 (2) 0/38 (0) 0/35 (0)
CBA/FISH and/or RQ-PCR
3 months* 186/223 (83) 148/173 (86) 38/50 (76) 36/47 (77)
6 months† 151/199 (76) 114/154 (74) 37/45 (82) 35/42 (83)
12 months‡ 117/170 (69) 95/132 (72) 22/38 (58) 21/35 (60)
Second TKI
RQ-PCR
3 months* 63/82 (77) 8/10 (80) 55/72 (76) 43/54 (80)
6 months† 44/66 (67) 4/8 (50) 40/58 (69) 31/46 (67)
12 months‡ 27/52 (52) 4/8 (50) 23/44 (52) 19/39 (49)
CBA or FISH
3 months* 12/82 (15) 2/10 (20) 10/72 (14) 9/54 (17)
6 months† 4/66 (6) 0/8 (0) 4/58 (7) 4/46 (9)
12 months‡ 1/52 (2) 0/8 (0) 1/44 (2) 1/39 (3)
CBA/FISH and/or RQ-PCR
3 months* 65/82 (79) 8/10 (80) 57/72 (79) 45/54 (83)
6 months† 45/66 (68) 4/8 (50) 41/58 (71) 32/46 (70)
12 months‡ 27/52 (52) 4/8 (50) 23/44 (52) 19/39 (49)
≥1 assessment at an ELN milestone (first- or second-line TKI)* 239/257 (93) 189/203 (93) 50/54 (93) 48/50 (96)
CBA, chromosome banding analysis; ELN, European LeukemiaNet; FISH, fluorescence in situ hybridisation; RQ-PCR, real-time quantitative poly-
merase chain reaction; TKI, tyrosine kinase inhibitor.
*Denominator included patients with ≥4 months’ follow-up on that TKI.
†Denominator included patients with ≥7 months’ follow-up on that TKI.
‡Denominator included patients with ≥13 months’ follow-up on that TKI.
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tools, such as QRISK2, was rarely documented. Baseline
blood pressure was documented in fewer than one-third of
patients, and when baseline blood pressure was recorded, it
was often elevated, with three patients in hypertensive crisis,
illustrating the importance of documenting this parameter so
that hypertension can be managed appropriately. However,
some evidence was observed that CV comorbidities at base-
line played a role in first-line TKI choice, with patients
appearing more likely to receive first-line imatinib if a CV
comorbidity was documented.
Currently, the UK National Institute for Health and Care
Excellence (NICE) recommends NHS funding in England of
imatinib, nilotinib or dasatinib in the first line and nilotinib,
dasatinib, bosutinib or ponatinib in later lines.25 In this
cohort, first-line treatment was mostly imatinib or nilotinib
(<2% received first-line dasatinib), and second-line treatment
was mostly nilotinib, reflecting NICE recommendations at the
start of treatment for these patients (dasatinib was not rou-
tinely available). Patients were more likely to receive first-line
2G-TKIs than imatinib if they were younger and had no
Table IV. Summary of molecular responses to first-line TKI therapy.*



































EMR at 3 months (1 month), in
patients with 3-month molecular
response assessments, n (%)
88/163 (54) 29/41 (71) 117/204 (57) 88/156 (56) 28/38 (74) 26/36 (72) 116/194 (60)
MMR by 12 months (1 month), n (%) 84 (41) 28 (52) 112 (44) 71 (35) 26 (48) 25 (50) 97 (38)
MMR at any time, n (%) 156 (77) 42 (78) 198 (77) 102 (50) 34 (63) 32 (64) 136 (53)
DMR at any time, n (%) 95 (47) 35 (65) 130 (51) 58 (29) 29 (54) 27 (54) 87 (34)
2G-TKI, second-generation tyrosine kinase inhibitor; DMR, deep molecular response; EMR, early molecular response; IS, International Scale;
MMR, major molecular response.
*Patients could appear in multiple molecular response categories. Molecular responses were assessed as EMR (BCR-ABL1IS ≤10% at
three months), MMR (BCR-ABL1IS ≤01%) by 12 months, MMR at any time and DMR (BCR-ABL1IS ≤001%) at any time. To account for varia-
tions in real-world appointment scheduling, a window of  one month was applied to ELN-defined time points; if multiple assessments were
available within the window, the one closest to the time point was used.
†Fifty patients received first-line nilotinib, and four received first-line dasatinib.
‡The columns for overall response reported the duration of follow-up for all TKI therapies, including later-line TKIs in patients who switched
from their first-line TKI (from start of first-line TKI to most recent data collection, akin to an intention-to-treat analysis). The columns for first-
line TKI therapy reported the duration of follow-up for only first-line TKI therapy (from start of first-line TKI to most recent data collection or
death in patients who continued receiving first-line TKI or to end of first-line TKI for patients who switched to a second-line TKI).
600 12 24 36 48























38 21 12 6
Fig 1. Kaplan-Meier curve: time to discontinu-
ation of first-line TKI. Patients who had not
switched from first TKI at point of data collec-
tion were censored at date of data collection or
death. Months on first TKI were unknown for
10 patients on imatinib. TKI, tyrosine kinase
inhibitor.
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documented comorbidities. Overall, prognostic scores were
poorly documented despite strong evidence that these risk
scores remain highly predictive of disease response in the TKI
era.14 We did not find evidence that prognostic scores played
a major role in first-line TKI choice, with a majority of
patients identified as high risk by Sokal, EUTOS or Hasford
criteria being treated with imatinib. Overall, 4% of patients
progressed to AP and/or BP, corresponding well with the
results of the Swedish CML registry (3% by 12 months).2
One key finding of this study is that ELN 2013 monitoring
recommendations were not consistently implemented.
Patients frequently did not have assessments at recom-
mended time points. This finding is consistent with those
from the SIMPLICITY study, which reported that monitor-
ing was conducted less frequently than recommended,
although with higher frequency in Europe than the United
States.23 This finding is important because a previous study
showed that patients without frequent molecular monitoring






















































Fig 2. TKI treatment pathways and molecular responses for patients with ELN optimal, warning (at single versus multiple ELN milestones) or
failure responses while on first-line TKI. aTo account for variations in real-world appointment scheduling, a window of  one month was applied
to ELN-defined time points (three, six and 12 months). In patients with multiple test results available, any patient with a failure response to first-
line TKI at an ELN milestone (regardless of other responses achieved at earlier milestones) was classified as having a failure response. Patients in
the optimal category had only optimal responses at an ELN milestone (three, six or 12 months) with either molecular or cytogenetic assessment
(where a molecular test was not available). Patients in the warning category had a warning at any milestone with either assessment but had no
failure at any milestone with either assessment. Patients without assessments at any ELN milestone could not be categorised. Thirty-four patients
had no evaluable test at any ELN milestone by either molecular or cytogenetic test. bResponse may have been observed at any time. Duration of
follow-up varied; patient may have had ≥ one subsequent TKI switch. Forty-eight patients had ≥ one failure; 11 (23%) remained on first-line TKI
[median follow-up, 138 months (IQR, 128–259 months)], and 37 (77%) switched TKIs [median follow-up, 251 months (IQR, 143–
326 months)]. Of those who switched, 22 had their first failure at six months (BCR-ABL1IS range, 101%-601%; two patients had a failure
according to FISH), and 15 had their first failure at 12 months (BCR-ABL1IS range, 12–127%). Among these patients with a failure who
switched TKIs, 17 (46%) and 10 (27%) achieved MMR and DMR at any time, respectively, vs. four (36%) and no patients, who did not switch
TKIs. Of 81 patients with warning but no failure, 52 (64%) remained on first-line TKI [median follow-up 284 months (IQR, 137–
404 months)], and 29 (36%) switched TKIs [median follow-up 309 months (IQR, 203–383 months)]. Of those who switched TKIs, 19/29 had
≥1 additional RQ-PCR assessment between the initial warning and TKI switch. Of 34 patients without any quantifiable assessment at any ELN
milestone, 27 (79%) switched TKIs. cOf 48 patients with ELN-defined failure responses, 39 were treated with imatinib as first-line therapy and
nine with a 2G-TKI; 38 patients (79%) also had an ELN-defined warning at a prior ELN time point (with either a molecular or cytogenetic test).
DMR, deep molecular response; ELN, European LeukemiaNet; EMR, early molecular response; FISH, fluorescence in situ hybridisation; IQR,
interquartile range; IS, International Scale; MMR, major molecular response; RQ-PCR, real-time quantitative polymerase chain reaction; TKI, tyr-
osine kinase inhibitor.
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were at higher risk of disease progression.26 In addition, fre-
quent molecular monitoring (3–4 times per year) was associ-
ated with greater TKI treatment adherence in patients with
CML.27
Overall, in our study, 86% of patients had ≥3 molecular
response tests during their first year of TKI treatment, while
SIMPLICITY reported 46% for Europe,23 a finding which
potentially reflects UK-specific practice or changes in practice
over time (UK patients who were first treated in 2013–2017
were compared with SIMPLICITY patients first treated in
2010–2015). Furthermore, our UK study observed a relatively
high level of testing for early molecular response (EMR) at
three months (81%) compared with SIMPLICITY (32%),
indicating rapid adoption of molecular monitoring at early
milestones in the UK.23
However, despite a generous one-month window applied
around ELN milestones, a large proportion of patients (20–
30%) were still without evaluable molecular or cytogenetic
test results at any given time point during their first year of
TKI treatment. Moreover, 13% of patients had no evaluable
molecular or cytogenetic result at any ELN milestone during
the first year of TKI treatment.
ELN recommended that a patient with ELN-defined fail-
ure should have their TKI switched to reduce the risk of pro-
gression. Nevertheless, a number of patients in TARGET
remained on first-line TKI despite ELN-defined treatment
failure.
Strikingly, BCR-ABL1 kinase domain mutational analyses,
recommended by ELN in warning or failure, were infre-
quently performed, even in patients with documented resis-
tance, despite the known importance of mutation status for
subsequent TKI selection. Patients did not always have rec-
ommended baseline assessments such as qualitative PCR
despite its importance in determining BCR-ABL1 transcript
type, which can affect future molecular monitoring, especially
at the low levels before consideration for TFR. Furthermore,
although bone marrow and cytogenetic analysis still have an
essential role in assessment of patients at baseline, many
patients were managed without bone marrow or cytogenetic
analysis. Bone marrow evaluation before TKI switching was
infrequently performed, which may reflect the current use of
PCR thresholds for interpretation of resistance.
Clinical trials have shown that 2G-TKIs lead to improved
rates of molecular responses compared with imatinib.12–14 In






















Median follow-up post first
switch (range), months§
237 (12–541) 225 (49–430) 239 (12–541) 297 (12–524) 274 (12–514) 201 (28–541)
Median follow-up on second-













EMR at 3 months (1 month)
on second TKI in patients with
3-month molecular response
assessments, n (%)**
59/70 (84) 10/10 (100) 49/60 (82) 38/45 (84) 39/47 (83) 20/23 (87)
MMR by 12 months (1 month)
on second TKI, n (%)††
30/50 (60) 4/7 (57) 26/43 (60) 24/38 (63) 21/35 (60) 9/15 (60)
MMR at any time on second
;TKI, n (%)††
37/51 (73) 4/8 (50) 33/43 (77) 29/38 (76) 27/36 (75) 10/15 (67)
DMR at any time on second
TKI, n (%)††
21/51 (41) 2/8 (25) 19/43 (44) 17/38 (45) 15/36 (42) 6/15 (40)
2G-TKI, second-generation tyrosine kinase inhibitor; DMR, deep molecular response; EMR, early molecular response; IS, International Scale;
MMR, major molecular response.
*Patients could appear in multiple molecular response categories. Molecular responses after switch to second TKI were assessed as EMR (BCR-
ABL1IS ≤10% at three months), MMR (BCR-ABL1IS ≤01%) by 12 months, MMR at any time and DMR (BCR-ABL1IS ≤001%) at any time. To
account for variations in real-world appointment scheduling, a window of  one month was applied to ELN-defined time points; if multiple
assessments were available within the window, the one closest to the time point was used.
†Switched to 2G-TKI (n = 68 nilotinib, n = 20 dasatinib, n = 11 bosutinib, n = 1 ponatinib).
‡Switched for intolerance (n = 38) or switched for another reason (n = 2).
§Duration from start of second-line TKI to last data collection or death (included patients with ≥1 switch).
¶Duration from start of second-line TKI to last data collection, date of switch to a third-line TKI, or death.
**EMR defined as BCR-ABL1IS ≤10% at three months (1 month); only those patients with BCR-ABL1 available at three months were included.
††MMR (≤01% BCR-ABL1); DMR (≤001% BCR-ABL1); only those patients with ≥13 months’ follow-up were included.
D. Milojkovic et al.
10
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology and
John Wiley & Sons Ltd
this cohort, observed rates of EMR and MMR at ELN mile-
stones and DMR at any time during first-line TKI were
higher with 2G-TKIs than with imatinib, confirming the
results in this real-world setting. While EMR and MMR were
defined as optimal responses in ELN 2013,4 treatment goals
are evolving to include deeper responses and TFR.8,10,11
Studies have shown that deeper molecular responses were
associated with improved outcomes compared with complete
cytogenetic response,6,7 and a sustained DMR is a prerequi-
site for attempting TFR in both clinical practice guideli-
nes8,10,11 and clinical trials.28,29 Clinical studies have
demonstrated that 2G-TKIs can also lead to improved rates
of DMR in the second line.30 Results from our study showed
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Fig 3. Disease progressiona. aEight patients (seven on imatinib, one on a second-generation TKI) progressed to accelerated phase (AP) during the
course of the study. The median time to progression was 165 months (range, 21–311; IQR, 75–264; time to progression was unknown for one
patient on first-line imatinib). Three patients had a prior warning response at an ELN milestone (all three received imatinib as first TKI), and
three patients had a failure response at an ELN milestone (two received imatinib first-line and one received nilotinib). The other two patients
who progressed to AP had no prior evaluable response at an ELN milestone (both patients received first-line imatinib). Treatments for progres-
sion to AP were TKIs in three patients, chemotherapy in four patients and allogeneic haematopoietic stem cell transplant (HSCT) in five patients.
Six patients progressed to BP (all received first-line imatinib), including four who were previously recorded as progressing to AP. Median time
from start of first-line TKI to progression to BP was 227 months (range 12–321; IQR, 172–301). Treatments for progression to BP were TKIs
in four patients, chemotherapy in four patients, allogeneic HSCT in two patients and haploidentical allogeneic HSCT in one patient. Among four
patients who progressed to AP only, two received one TKI prior to progression, one received three TKIs prior to progression, and one had an
unknown date of disease progression. Among four patients who progressed to AP and BP, two each received one or two TKIs prior to their earli-
est progression, respectively. Among two patients who progressed to BP only, one each received one or two TKIs prior to progression, respec-
tively. None of the patients who progressed were observed to have only ELN-optimal responses to first-line TKI; three patients had ≥ one failure,
four had ≥ one warning and two had no available assessments at ELN milestones. In the 10 patients who progressed to AP and/or BP, the base-
line Sokal score was recorded as high for four, intermediate for two, low for one and unknown for three. bA total of 15/257 patients died during
the study observation period; five of these patients had progressed to AP and/or BP prior to death (n = 4 had blast crisis prior to death). Another
five patients had progressed but were still alive at data collection (n = 2 had blast crisis); all had received alternative treatment with four of five
receiving both transplant and chemotherapy after progressing (n = 1 after alternative TKI); the other patient received a transplant only. AP, accel-
erated phase; BP, blast phase; ELN, European LeukemiaNet; TKI, tyrosine kinase inhibitor.
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not only optimal responses but also deeper responses,
including patients with prior resistance or ELN-defined
failure.
A criticism of observational studies is the increased risk of
selection bias and confounding, precluding the robust analysis
and conclusions provided by randomised controlled trials.
However, real-world evidence plays an important role in
allowing physicians to reflect on current practice. Our study
demonstrated that almost half of patients required a TKI
switch in real-world practice and that optimal and deep
responses can be achieved by patients who switch. However,
inadequate CV risk assessment, response monitoring, and
mutational analysis increased the risk of inappropriate patient
management and, as such, the findings of this study high-
lighted key areas for improvement in care for patients with
CML. Further consideration for improving implementation of
guidelines in real-world clinical practice, including very recent
updates to the ELN recommendations,31 is warranted.
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